мÓÆÂÁùºÏ²Ê¿ª½±Ö±²¥

 CCfV is now enrolling female volunteers ages 16-40 for a cytomegalovirus (CMV) vaccine clinical trial. Ìý
 
CMV is a common viral infection that usually goes unnoticed or only causes mild symptoms in most people. But if a woman becomes infected with CMV while she is pregnant, she can pass the infection to her unborn baby. This can cause her child to have long-term disability due to birth defects, including hearing loss, or even death in very severe cases. Currently, there is no approved vaccine against this virus.
 
The purpose of this clinical trial is to:

1. Evaluate the safety and effectiveness of an investigational vaccine (a vaccine not yet approved by Canada's drug regulatory agency) called mRNA-1647 against cytomegalovirus (CMV) infection in women who have not had priorCMV infection andÌý
2. Evaluate its safety in women who test positive for CMV due to prior exposure.
   

To join this clinical trial, you must be:

• A woman between 16-40 years of age
• In good health
• Not pregnant or planning on becoming pregnant within the next 9 months
• In close contact with at least one child 5 years of age or younger for at least 8 hours a week, if age 20 or older
  

For more information visit the CCfV websiteÌý or contact:
 
Krystal Lariviere
Canadian Center for Vaccinology
Tel: (902) 470-8141
Email: ccfv@iwk.nshealth.ca
Ìý